The ‍Decision and Its Impact

In a first-in-the-nation move, the Colorado Prescription drug affordability Board voted‍ on august 22, 2023, to limit how much health plans in the state will‍ pay for Enbrel, a costly medication manufactured by Amgen. This decision establishes an upper ⁤payment⁤ limit (UPL) for the drug,effectively creating ⁣a ‍ceiling on reimbursement rates ⁢for both government and ⁣commercial health insurance plans covering Colorado residents.

The UPL ‍is set at $600 per unit, aligning with the maximum fair price for Enbrel scheduled to take effect in the⁢ Medicare program in January 2024. This translates to ⁤an approximate annual cost‍ of $30,350 per‍ patient, a‍ notable reduction from the roughly $53,000 currently ⁣paid by the average Colorado insurance plan, according to data ⁤presented⁣ to the board.

Enbrel is a biologic drug, meaning it’s‍ made ⁢from living organisms and is significantly more⁤ expensive than traditional medications. it’s used to treat a range ‍of autoimmune ⁤diseases, including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. ⁤ The high cost‍ of these‍ types of⁢ drugs is a major driver of increasing healthcare expenses.

How Colorado’s Board⁤ Works

The Colorado ⁣Prescription Drug Affordability Board was created in 2022 through House ⁣Bill 22-1283, aiming to address rising prescription drug costs. The seven-member board is⁣ composed of healthcare professionals, ‍economists, and consumer advocates. Its ⁢primary function is⁢ to review prescription ‍drug prices and ‍establish⁢ UPLs for medications deemed ⁣unaffordable.

The board’s authority is limited to setting UPLs; it cannot directly negotiate drug ⁢prices with manufacturers. However, the expectation is that these limits will incentivize manufacturers ⁤to offer lower prices to maintain market access in⁢ Colorado. ⁤ The ⁢board selected Enbrel for⁣ its initial UPL review due to its high cost⁣ and the availability⁣ of alternative treatments.

National Implications and Potential for Expansion

Colorado’s action is being closely watched by other states grappling with high drug prices. ‍ Several states, including ⁤ California, Maryland, and Washington, have enacted legislation to explore similar strategies for controlling drug ⁤costs. ‍ The success of Colorado’s⁤ UPL program could encourage these states to implement⁤ their own payment limits.

The federal government is also taking steps to lower drug prices. The Inflation Reduction Act of 2022, signed into law on⁢ August 16, 2022, ⁢allows Medicare to negotiate prices‍ for certain high-cost drugs, starting in ⁤2026. Colorado’s initiative complements these ‍federal efforts by addressing‍ affordability concerns in the commercial⁤ market.